| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
ElteN378 targets specific cellular pathways involved in disease. The compound's mechanism of action involves modulation of key signaling proteins or enzymes. By targeting these pathways, ElteN378 exerts its biological effects. The compound's selectivity for its target influences its therapeutic potential and safety profile.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, ElteN378 modulates the activity of its target proteins. The compound's effects on target enzymes or receptors can be assessed using purified proteins and appropriate assays. The IC50 or EC50 is determined from dose-response curves. The compound's selectivity can be assessed by testing against a panel of related targets.
|
| ln Vivo |
In cell-based assays, ElteN378 modulates cellular signaling pathways and exerts its biological effects. The compound's effects are evaluated in relevant cell lines by measuring cell viability, proliferation, apoptosis, and other functional endpoints. The compound's mechanism of action is studied by assessing the modulation of downstream signaling pathways.
|
| Enzyme Assay |
The cell-free assay for ElteN378 involves measuring the activity of its target protein in the presence of the compound. The specific assay depends on the target and may involve enzymatic activity measurements, binding assays, or other biochemical techniques. The IC50 or EC50 is determined from dose-response curves. The compound's selectivity is assessed by testing against a panel of related targets.
|
| Cell Assay |
Cell-based assays for ElteN378 involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.001 to 100 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. The compound's effects on signaling pathways are assessed by Western blotting or other techniques. Apoptosis, cell cycle distribution, and other functional endpoints are evaluated as appropriate.
|
| Animal Protocol |
In animal models, ElteN378 has been evaluated for its efficacy in disease models. Typical studies involve administration of the compound to mice via oral, intraperitoneal, or intravenous routes at doses determined from toxicity studies. Disease progression, biomarker modulation, and survival are assessed. Tissues are collected for analysis of target engagement and pathway modulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ElteN378 have been characterized in preclinical studies. The compound's oral bioavailability, plasma half-life, clearance, and tissue distribution have been determined. The compound's pharmacokinetic properties influence its dosing regimen and therapeutic potential. Further studies may be required to fully characterize its metabolism and elimination.
|
| Toxicity/Toxicokinetics |
ElteN378 is an investigational compound and its toxicity profile is being evaluated in preclinical studies. Standard toxicology studies in animal models are conducted to determine the maximum tolerated dose, target organ toxicity, and safety profile. The compound's safety profile influences its potential for clinical development.
|
| References | |
| Additional Infomation |
ElteN378 is an investigational compound being studied for its potential therapeutic applications. It is not an approved pharmaceutical and has no clinical trial history. The compound is a small molecule targeting specific cellular pathways. This product is intended for research use only.
|
| Molecular Formula |
C23H26N2O3
|
|---|---|
| Molecular Weight |
378.4641
|
| Exact Mass |
378.194
|
| CAS # |
1421366-99-5
|
| PubChem CID |
71563275
|
| Appearance |
White to off-white ointment
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCN([C@@H](C1)C(=O)NCCCC2=CC=CC=C2)C(=O)C(=O)C3=CC=CC=C3
|
| InChi Key |
QXYDCLICGYMGIX-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C23H26N2O3/c26-21(19-13-5-2-6-14-19)23(28)25-17-8-7-15-20(25)22(27)24-16-9-12-18-10-3-1-4-11-18/h1-6,10-11,13-14,20H,7-9,12,15-17H2,(H,24,27)/t20-/m0/s1
|
| Chemical Name |
(2S)-1-(2-oxo-2-phenylacetyl)-N-(3-phenylpropyl)piperidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6423 mL | 13.2114 mL | 26.4229 mL | |
| 5 mM | 0.5285 mL | 2.6423 mL | 5.2846 mL | |
| 10 mM | 0.2642 mL | 1.3211 mL | 2.6423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
